| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 15.1017 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 15.1017. The average price that 007390.KQ shares were previous bought at was KRW 21.5605. The current market price is -30.0% lower than average price they were purchased at. The value of the holding in 007390.KQ has fallen by KRW 54,911 (USD $37) compared to the previous valuation of NatureCell Co.,Ltd. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 37.2465 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 37.2465. The average price that 039200.KQ shares were previous bought at was KRW 20.0221. The current market price is 86.0% higher than average price they were purchased at. The value of the holding in 039200.KQ has increased by KRW 7,218 (USD $5) compared to the previous valuation of Oscotec Inc. however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 123.32 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 123.32. The average price that 068270.KS shares were previous bought at was KRW 121.344. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in 068270.KS has fallen by KRW 459,393 (USD $313) compared to the previous valuation of CELLTRION INC |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 16.5578 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 16.5578. The average price that 096530.KQ shares were previous bought at was KRW 17.6796. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 2,487 (USD $2) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.86592 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.86592. The average price that 13.HK shares were previous bought at was HKD 3.03049. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 32,802 (USD $4,215) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 4.22358 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.05869 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.05869. The average price that 1877.HK shares were previous bought at was HKD 2.20212. The current market price is 38.9% higher than average price they were purchased at. The value of the holding in 1877.HK has increased by HKD 8,588 (USD $1,104) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.40255 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.40255. The average price that 2162.HK shares were previous bought at was HKD 5.23181. The current market price is 41.5% higher than average price they were purchased at. The value of the holding in 2162.HK has increased by HKD 38,446 (USD $4,940) compared to the previous valuation of KEYMED BIOSCIENCES INC however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 2.79395 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 2.79395. The average price that 2252.HK shares were previous bought at was HKD 3.78461. The current market price is -26.2% lower than average price they were purchased at. The value of the holding in 2252.HK has increased by HKD 31,158 (USD $4,004) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 66.5019 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 66.5019. The average price that 237690.KQ shares were previous bought at was KRW 54.2929. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in 237690.KQ has fallen by KRW 16,993 (USD $12) compared to the previous valuation of ST Pharm Co.,Ltd. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 117.225 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 117.225. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 191.7% higher than average price they were purchased at. The value of the holding in 298380.KQ has fallen by KRW 169,371 (USD $115) compared to the previous valuation of ABL Bio Inc. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 34.6731 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 34.6731. The average price that 302440.KS shares were previous bought at was KRW 36.225. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 26,512 (USD $18) compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 86.8859 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 86.8859. The average price that 326030.KS shares were previous bought at was KRW 73.1926. The current market price is 18.7% higher than average price they were purchased at. The value of the holding in 326030.KS has increased by KRW 39,872 (USD $27) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 24.6504 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 24.6504. The average price that 328130.KQ shares were previous bought at was KRW 36.9599. The current market price is -33.3% lower than average price they were purchased at. The value of the holding in 328130.KQ has increased by KRW 46,973 (USD $32) compared to the previous valuation of Lunit Inc. however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.5422 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.5422. The average price that 3933.HK shares were previous bought at was HKD 1.74455. The current market price is -11.6% lower than average price they were purchased at. The value of the holding in 3933.HK has increased by HKD 40,252 (USD $5,172) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.8288 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.8288. The average price that 4523.T shares were previous bought at was JPY 28.0807. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 16,128 (USD $103) compared to the previous valuation of Eisai Co., Ltd. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 14.9431 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 14.9431. The average price that 4549.T shares were previous bought at was JPY 13.6521. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in 4549.T has fallen by JPY 665 (USD $4) compared to the previous valuation of Eiken Chemical Co., Ltd. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.6445 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.6445. The average price that 4587.T shares were previous bought at was JPY 11.461. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 2,082 (USD $13) compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 12.1401 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 12.1401. The average price that 4887.T shares were previous bought at was JPY 13.3982. The current market price is -9.4% lower than average price they were purchased at. The value of the holding in 4887.T has fallen by JPY 2,225 (USD $14) compared to the previous valuation of Sawai Group Holdings Co., Ltd. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.28715 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.28715. The average price that 4974.T shares were previous bought at was JPY 5.90785. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in 4974.T has fallen by JPY 475 (USD $3) compared to the previous valuation of Takara Bio Inc. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.93973 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.93973. The average price that 6869.T shares were previous bought at was JPY 17.8798. The current market price is -44.4% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 9,592 (USD $61) compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 29.2292 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 29.2292. The average price that 6951.T shares were previous bought at was JPY 33.4997. The current market price is -12.7% lower than average price they were purchased at. The value of the holding in 6951.T has fallen by JPY 2,805 (USD $18) compared to the previous valuation of JEOL Ltd. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 9.4901 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 9.4901. The average price that 7575.T shares were previous bought at was JPY 10.3645. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in 7575.T has fallen by JPY 1,021 (USD $7) compared to the previous valuation of Japan Lifeline Co., Ltd. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 27.7943 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 27.7943. The average price that 7701.T shares were previous bought at was JPY 25.4348. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in 7701.T has fallen by JPY 15,173 (USD $97) compared to the previous valuation of Shimadzu Corporation |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 18.4508 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 18.4508. The average price that 7747.T shares were previous bought at was JPY 16.4838. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in 7747.T has fallen by JPY 8,531 (USD $54) compared to the previous valuation of Asahi Intecc Co., Ltd. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 10.6669 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 10.6669. The average price that 9995.HK shares were previous bought at was HKD 9.31045. The current market price is 14.6% higher than average price they were purchased at. The value of the holding in 9995.HK has increased by HKD 56,558 (USD $7,268) compared to the previous valuation of REMEGEN LTD H however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 153.6 | USD 0 | The current share valuation price of A based on adjusted close was USD 153.6. The average price that A shares were previous bought at was USD 118.65. The current market price is 29.5% higher than average price they were purchased at. The value of the holding in A has increased by USD 289,599 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 229.51 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 229.51. The average price that ABBV shares were previous bought at was USD 191.211. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 530,565 compared to the previous valuation of AbbVie Inc |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.57 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.57. The average price that ABCL shares were previous bought at was USD 3.29477. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in ABCL has increased by USD 15,431 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 127.19 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 127.19. The average price that ABT shares were previous bought at was USD 124.109. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in ABT has fallen by USD 101,856 compared to the previous valuation of Abbott Laboratories |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 23.9 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 23.9. The average price that ACAD shares were previous bought at was USD 17.44. The current market price is 37.0% higher than average price they were purchased at. The value of the holding in ACAD has increased by USD 50,469 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 74.96 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 74.96. The average price that ACLX shares were previous bought at was USD 63.8126. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in ACLX has fallen by USD 763,358 compared to the previous valuation of Arcellx Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 20.46 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 20.46. The average price that ADPT shares were previous bought at was USD 6.33052. The current market price is 223.2% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 342,759 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 28.2 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 28.2. The average price that ALKS shares were previous bought at was USD 31.5876. The current market price is -10.7% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 81,222 compared to the previous valuation of Alkermes Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 334.3 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 334.3. The average price that AMGN shares were previous bought at was USD 287.725. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 163,980 compared to the previous valuation of Amgen Inc |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 14.82 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 14.82. The average price that AMLX shares were previous bought at was USD 11.84. The current market price is 25.2% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 13,487 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 41.95 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 41.95. The average price that ANAB shares were previous bought at was USD 22.9035. The current market price is 83.2% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 61,310 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.32998 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.32998. The average price that ARCT shares were previous bought at was USD 16.4363. The current market price is -61.5% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 1,851 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 11.77 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 11.77. The average price that ARVN shares were previous bought at was USD 11.3332. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 21,438 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 22.6 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 22.6. The average price that ASTH shares were previous bought at was USD 27.1156. The current market price is -16.7% lower than average price they were purchased at. The value of the holding in ASTH has increased by USD 4,914 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 37.74 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 37.74. The average price that ATRC shares were previous bought at was USD 33.1524. The current market price is 13.8% higher than average price they were purchased at. The value of the holding in ATRC has increased by USD 94,491 compared to the previous valuation of AtriCure Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 16.11 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 16.11. The average price that AUPH shares were previous bought at was USD 8.80384. The current market price is 83.0% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 69,480 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 28.39 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 28.39. The average price that AXGN shares were previous bought at was USD 16.8496. The current market price is 68.5% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 81,389 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 151.2 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 151.2. The average price that AXSM shares were previous bought at was USD 105.595. The current market price is 43.2% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 81,284 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BANB.SW - | HOLD | 0 @ CHF 61.607 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 61.607. The average price that BANB.SW shares were previous bought at was CHF 65.1273. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 17,798 (USD $22,009) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 28.7143 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 28.7143. The average price that BAVA.CO shares were previous bought at was DKK 24.9137. The current market price is 15.3% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 36,492 (USD $5,623) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 6.83 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 6.83. The average price that BCRX shares were previous bought at was USD 7.80196. The current market price is -12.5% lower than average price they were purchased at. The value of the holding in BCRX has fallen by USD 35,024 compared to the previous valuation of BioCryst Pharmaceuticals Inc |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 23.62 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 23.62. The average price that BEAM shares were previous bought at was USD 17.8287. The current market price is 32.5% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 170,328 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 176.82 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 176.82. The average price that BIIB shares were previous bought at was USD 128.1. The current market price is 38.0% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 166,690 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 125.326 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 125.326. The average price that BIM.PA shares were previous bought at was EUR 119.434. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 85,038 (USD $97,858) compared to the previous valuation of BioMerieux however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 322.48 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 322.48. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 149,049 compared to the previous valuation of Bio-Rad Laboratories Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 322.48 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 322.48. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 149,049 compared to the previous valuation of Biotest Aktiengesellschaft however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BIOA-B.ST - | HOLD | 0 @ SEK 31.4982 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 31.4982. The average price that BIOA-B.ST shares were previous bought at was SEK 23.3486. The current market price is 34.9% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 112,568 (USD $11,800) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 26.35 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 26.35. The average price that BLFS shares were previous bought at was USD 26.74. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in BLFS has fallen by USD 10,279 compared to the previous valuation of BioLife Solutions Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 47.76 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 47.76. The average price that BMY shares were previous bought at was USD 54.5268. The current market price is -12.4% lower than average price they were purchased at. The value of the holding in BMY has increased by USD 449,066 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 98.04 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 98.04. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in BSX has increased by USD 173,379 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 98.04 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 98.04. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in BSX has increased by USD 173,379 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CDNA - Caredx Inc | HOLD | 0 @ USD 17.96 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 17.96. The average price that CDNA shares were previous bought at was USD 19.5286. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in CDNA has increased by USD 48,888 compared to the previous valuation of Caredx Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CERT - Certara Inc | HOLD | 0 @ USD 8.86 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 8.86. The average price that CERT shares were previous bought at was USD 10.5583. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in CERT has increased by USD 31,286 compared to the previous valuation of Certara Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 43.56 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 43.56. The average price that CGON shares were previous bought at was USD 33.16. The current market price is 31.4% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 82,400 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CHEMM.CO - | HOLD | 0 @ DKK 116.864 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 116.864. The average price that CHEMM.CO shares were previous bought at was DKK 73.2155. The current market price is 59.6% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 24,358 (USD $3,753) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 23.51 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 23.51. The average price that CPRX shares were previous bought at was USD 22.1952. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in CPRX has increased by USD 33,701 compared to the previous valuation of Catalyst Pharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CRL - Creightons Plc | HOLD | 0 @ USD 170.44 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 170.44. The average price that CRL shares were previous bought at was USD 161.828. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in CRL has increased by USD 166,676 compared to the previous valuation of Creightons Plc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CRVL - CorVel Corp | HOLD | 0 @ USD 73.88 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 73.88. The average price that CRVL shares were previous bought at was USD 112.167. The current market price is -34.1% lower than average price they were purchased at. The value of the holding in CRVL has increased by USD 1,084 compared to the previous valuation of CorVel Corp however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 38.49 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 38.49. The average price that CSTL shares were previous bought at was USD 19.5501. The current market price is 96.9% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 21,485 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 5.84 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 5.84. The average price that CTKB shares were previous bought at was USD 5.75945. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in CTKB has fallen by USD 6,399 compared to the previous valuation of Cytek Biosciences Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 8.88 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 8.88. The average price that DAWN shares were previous bought at was USD 7.37. The current market price is 20.5% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 33,459 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 226.98 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 226.98. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 30,053 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 226.98 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 226.98. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 30,053 compared to the previous valuation of Danaher Corporation |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 69.9379 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 69.9379. The average price that DIA.MI shares were previous bought at was EUR 51.5128. The current market price is 35.8% higher than average price they were purchased at. The value of the holding in DIA.MI has increased by EUR 46,213 (USD $53,180) compared to the previous valuation of DiaSorin SpA however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.44 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.44. The average price that DVAX shares were previous bought at was USD 12.9918. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in DVAX has increased by USD 37,492 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 62.21 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 62.21. The average price that DXCM shares were previous bought at was USD 79.7195. The current market price is -22.0% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 346,950 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 9.61282 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 9.61282. The average price that DYVOX.ST shares were previous bought at was SEK 6.01864. The current market price is 59.7% higher than average price they were purchased at. The value of the holding in DYVOX.ST has increased by SEK 44,616 (USD $4,677) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| EKTA-B.ST - | HOLD | 0 @ SEK 4.54881 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 4.54881. The average price that EKTA-B.ST shares were previous bought at was SEK 5.55917. The current market price is -18.2% lower than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 57,633 (USD $6,041) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 14.64 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 14.64. The average price that EMBC shares were previous bought at was USD 15.31. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in EMBC has increased by USD 4,911 compared to the previous valuation of Embecta Corp however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 18.6086 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 18.6086. The average price that EUZ.DE shares were previous bought at was EUR 20.0666. The current market price is -7.3% lower than average price they were purchased at. The value of the holding in EUZ.DE has increased by EUR 42,829 (USD $49,286) compared to the previous valuation of Eckert & Ziegler SE however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 4.27 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 4.27. The average price that EVH shares were previous bought at was USD 10.5742. The current market price is -59.6% lower than average price they were purchased at. The value of the holding in EVH has increased by USD 16,785 compared to the previous valuation of Evolent Health Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.11064 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.11064. The average price that EVT.DE shares were previous bought at was EUR 6.57563. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 22,478 (USD $25,867) compared to the previous valuation of Evotec SE however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.71 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.71. The average price that EW shares were previous bought at was USD 73.5436. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 82,287 compared to the previous valuation of Edwards Lifesciences Corp |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 101.01 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 101.01. The average price that EXAS shares were previous bought at was USD 51.941. The current market price is 94.5% higher than average price they were purchased at. The value of the holding in EXAS has increased by USD 25,083 compared to the previous valuation of EXACT Sciences Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 42.25 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 42.25. The average price that EXEL shares were previous bought at was USD 36.0106. The current market price is 17.3% higher than average price they were purchased at. The value of the holding in EXEL has fallen by USD 85,666 compared to the previous valuation of Exelixis Inc |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 11.95 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 11.95. The average price that FTRE shares were previous bought at was USD 10.2008. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 118,287 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 111.25 | USD 0 | The current share valuation price of GH based on adjusted close was USD 111.25. The average price that GH shares were previous bought at was USD 42.8441. The current market price is 159.7% higher than average price they were purchased at. The value of the holding in GH has increased by USD 876,098 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 125.27 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 125.27. The average price that GILD shares were previous bought at was USD 102.696. The current market price is 22.0% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 184,800 compared to the previous valuation of Guild Esports Plc |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 30.9452 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 30.9452. The average price that GLPG.AS shares were previous bought at was EUR 28.0716. The current market price is 10.2% higher than average price they were purchased at. The value of the holding in GLPG.AS has increased by EUR 19,334 (USD $22,249) compared to the previous valuation of Galapagos NV however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 309.683 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 309.683. The average price that GMAB.CO shares were previous bought at was DKK 214.002. The current market price is 44.7% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 429,975 (USD $66,257) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.4969 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.4969. The average price that GSK.L shares were previous bought at was GBP 18.3574. The current market price is 28.0% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 72,237 (USD $94,604) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 74 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 74. The average price that HALO shares were previous bought at was USD 58.3208. The current market price is 26.9% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 545,618 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.86674 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.86674. The average price that HLUN-B.CO shares were previous bought at was DKK 5.84339. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 20,839 (USD $3,211) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.76 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.76. The average price that HOLX shares were previous bought at was USD 65.3166. The current market price is 14.5% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 91,186 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 35.27 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 35.27. The average price that HRMY shares were previous bought at was USD 32.4203. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in HRMY has increased by USD 51,452 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 12.48 | USD 0 | The current share valuation price of IART based on adjusted close was USD 12.48. The average price that IART shares were previous bought at was USD 21.5655. The current market price is -42.1% lower than average price they were purchased at. The value of the holding in IART has increased by USD 36,048 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.15 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.15. The average price that IBRX shares were previous bought at was USD 2.8497. The current market price is -24.6% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 19,564 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 34.67 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 34.67. The average price that IDYA shares were previous bought at was USD 21.9973. The current market price is 57.6% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 71,546 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 125.96 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 125.96. The average price that ILMN shares were previous bought at was USD 92.7376. The current market price is 35.8% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 356,082 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.5 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.5. The average price that IOVA shares were previous bought at was USD 2.4224. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in IOVA has increased by USD 87,829 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 147.116 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 147.116. The average price that IPN.PA shares were previous bought at was EUR 115.732. The current market price is 27.1% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 41,191 (USD $47,401) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 228.18 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 228.18. The average price that IQV shares were previous bought at was USD 158. The current market price is 44.4% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 304,906 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 568.48 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 568.48. The average price that ISRG shares were previous bought at was USD 526.895. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 192,895 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 31.53 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 31.53. The average price that JANX shares were previous bought at was USD 25.3297. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in JANX has increased by USD 184,139 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 206.05 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 206.05. The average price that JNJ shares were previous bought at was USD 155.455. The current market price is 32.5% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 204,108 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 41.97 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 41.97. The average price that KNSA shares were previous bought at was USD 37.01. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 19,832 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 11.73 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 11.73. The average price that KURA shares were previous bought at was USD 8.825. The current market price is 32.9% higher than average price they were purchased at. The value of the holding in KURA has increased by USD 53,418 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.42 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.42. The average price that LAB shares were previous bought at was USD 1.33. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in LAB has increased by USD 16,867 compared to the previous valuation of Standard Biotools Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 206.89 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 206.89. The average price that LGND shares were previous bought at was USD 112.221. The current market price is 84.4% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 177,497 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 60.46 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 60.46. The average price that LIVN shares were previous bought at was USD 41.8947. The current market price is 44.3% higher than average price they were purchased at. The value of the holding in LIVN has increased by USD 338,982 compared to the previous valuation of LivaNova PLC however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 56.49 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 56.49. The average price that LNTH shares were previous bought at was USD 85.3876. The current market price is -33.8% lower than average price they were purchased at. The value of the holding in LNTH has increased by USD 55,740 compared to the previous valuation of Lantheus Holdings Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 662.127 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 662.127. The average price that LONN.SW shares were previous bought at was CHF 624.949. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 16,476 (USD $20,374) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 103.2 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 103.2. The average price that MDT shares were previous bought at was USD 86.0044. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 337,844 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 618.49 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 618.49. The average price that MEDP shares were previous bought at was USD 334.192. The current market price is 85.1% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 773,804 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 87.73 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 87.73. The average price that MMS shares were previous bought at was USD 73.448. The current market price is 19.4% higher than average price they were purchased at. The value of the holding in MMS has increased by USD 196,079 compared to the previous valuation of LYXETFETUSITETFP however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 100.4 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 100.4. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 26.0% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 481,956 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 100.4 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 100.4. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 26.0% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 481,956 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 24.15 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 24.15. The average price that MRNA shares were previous bought at was USD 26.0014. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in MRNA has increased by USD 201,188 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 95.95 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 95.95. The average price that MRUS shares were previous bought at was USD 52.0801. The current market price is 84.2% higher than average price they were purchased at. The value of the holding in MRUS has increased by USD 14,358 compared to the previous valuation of Merus BV however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.68 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.68. The average price that MRVI shares were previous bought at was USD 2.94723. The current market price is 24.9% higher than average price they were purchased at. The value of the holding in MRVI has fallen by USD 11,122 compared to the previous valuation of Maravai Lifesciences Holdings Inc |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 7.73 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 7.73. The average price that MYGN shares were previous bought at was USD 8.86565. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in MYGN has increased by USD 38,767 compared to the previous valuation of Myriad Genetics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 141.25 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 141.25. The average price that NBIX shares were previous bought at was USD 124.213. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 69,021 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 5.86 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 5.86. The average price that NEOG shares were previous bought at was USD 10.6516. The current market price is -45.0% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 36,687 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 11.8707 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 11.8707. The average price that NEU.AX shares were previous bought at was AUD 6.49393. The current market price is 82.8% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 29,279 (USD $18,921) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 127.523 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 127.523. The average price that NOVN.SW shares were previous bought at was CHF 105.855. The current market price is 20.5% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 37,307 (USD $46,134) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 238.58 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 238.58. The average price that NTRA shares were previous bought at was USD 159.203. The current market price is 49.9% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 714,403 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 7.41 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 7.41. The average price that NUVB shares were previous bought at was USD 3.35. The current market price is 121.2% higher than average price they were purchased at. The value of the holding in NUVB has increased by USD 124,511 compared to the previous valuation of Nuvation Bio Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.63 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.63. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 29,413 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.63 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.63. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 29,413 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 12.53 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 12.53. The average price that NVCR shares were previous bought at was USD 23.2352. The current market price is -46.1% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 70,366 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.79436 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.79436. The average price that ONT.L shares were previous bought at was GBP 1.69938. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 45,887 (USD $60,095) compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.5 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.5. The average price that PACB shares were previous bought at was USD 1.30688. The current market price is 91.3% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 102,944 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.22 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.22. The average price that PFE shares were previous bought at was USD 24.2467. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 110,063 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.68677 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.68677. The average price that PHARM.AS shares were previous bought at was EUR 0.824707. The current market price is 104.5% higher than average price they were purchased at. The value of the holding in PHARM.AS has increased by EUR 48,335 (USD $55,622) compared to the previous valuation of Pharming Group NV however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 90.7372 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 90.7372. The average price that PHM.MC shares were previous bought at was EUR 87.6333. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in PHM.MC has increased by EUR 61,727 (USD $71,033) compared to the previous valuation of Pharma Mar SA however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PINC - Premier Inc | HOLD | 0 @ USD 28.26 | USD 0 | The current share valuation price of PINC based on adjusted close was USD 28.26. The average price that PINC shares were previous bought at was USD 26.81. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in PINC has increased by USD 8,903 compared to the previous valuation of Premier Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 167.927 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 167.927. The average price that PME.AX shares were previous bought at was AUD 163.975. The current market price is 2.4% higher than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 422,058 (USD $272,751) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 337.53 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 337.53. The average price that PODD shares were previous bought at was USD 275.459. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 316,143 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 190.855 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 190.855. The average price that PRAX shares were previous bought at was USD 39.42. The current market price is 384.2% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 515,279 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 79.83 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 79.83. The average price that PTCT shares were previous bought at was USD 49.1674. The current market price is 62.4% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 129,537 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 26.58 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 26.58. The average price that QDEL shares were previous bought at was USD 29.6453. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in QDEL has increased by USD 181,132 compared to the previous valuation of Quidel Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 47.3344 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 47.3344. The average price that QIA.DE shares were previous bought at was EUR 40.6149. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in QIA.DE has increased by EUR 233,191 (USD $268,347) compared to the previous valuation of QIAGEN NV however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 23.18 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 23.18. The average price that RCUS shares were previous bought at was USD 8.69153. The current market price is 166.7% higher than average price they were purchased at. The value of the holding in RCUS has increased by USD 101,020 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 167.26 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 167.26. The average price that RGEN shares were previous bought at was USD 136.541. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in RGEN has increased by USD 300,960 compared to the previous valuation of Repligen Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 12.23 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 12.23. The average price that RGNX shares were previous bought at was USD 8.37881. The current market price is 46.0% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 23,242 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.17 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.17. The average price that RLAY shares were previous bought at was USD 3.79905. The current market price is 115.1% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 240,253 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 397.672 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 397.672. The average price that RO.SW shares were previous bought at was CHF 367.716. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 10,255 (USD $12,681) compared to the previous valuation of |
| ROG.SW - | HOLD | 0 @ CHF 384.92 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 384.92. The average price that ROG.SW shares were previous bought at was CHF 304.279. The current market price is 26.5% higher than average price they were purchased at. The value of the holding in ROG.SW has fallen by CHF 232,290 (USD $287,249) compared to the previous valuation of |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 100.58 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 100.58. The average price that RVTY shares were previous bought at was USD 87.5022. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in RVTY has increased by USD 328,944 compared to the previous valuation of Revvity Inc. however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.33 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.33. The average price that RXRX shares were previous bought at was USD 5.16079. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 76,812 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 106.58 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 106.58. The average price that RYTM shares were previous bought at was USD 64.092. The current market price is 66.3% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 341,477 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 17.11 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 17.11. The average price that SDGR shares were previous bought at was USD 23.4925. The current market price is -27.2% lower than average price they were purchased at. The value of the holding in SDGR has increased by USD 45,092 compared to the previous valuation of Schrodinger Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 29.8856 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 29.8856. The average price that SECT-B.ST shares were previous bought at was SEK 27.1554. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 85,274 (USD $8,939) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| SFZN.SW - | HOLD | 0 @ CHF 88.6468 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 88.6468. The average price that SFZN.SW shares were previous bought at was CHF 124.687. The current market price is -28.9% lower than average price they were purchased at. The value of the holding in SFZN.SW has increased by CHF 16,775 (USD $20,744) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 17.18 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 17.18. The average price that SLP shares were previous bought at was USD 26.7306. The current market price is -35.7% lower than average price they were purchased at. The value of the holding in SLP has increased by USD 3,308 compared to the previous valuation of Sylvania Platinum Limited however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 18.91 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 18.91. The average price that SRPT shares were previous bought at was USD 57.6553. The current market price is -67.2% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 144,018 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 266.908 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 266.908. The average price that SRT3.DE shares were previous bought at was EUR 226.06. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 235,769 (USD $271,314) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 30.34 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 30.34. The average price that STOK shares were previous bought at was USD 11.6276. The current market price is 160.9% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 65,549 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 45.15 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 45.15. The average price that SUPN shares were previous bought at was USD 34.9586. The current market price is 29.2% higher than average price they were purchased at. The value of the holding in SUPN has fallen by USD 11,538 compared to the previous valuation of Supernus Pharmaceuticals Inc |
| SXS.L - Spectris PLC | HOLD | 0 @ GBP 53.8307 | GBP 0 | The current share valuation price of SXS.L based on adjusted close was GBP 53.8307. The average price that SXS.L shares were previous bought at was GBP 55.4271. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in SXS.L has increased by GBP 8,757 (USD $11,468) compared to the previous valuation of Spectris PLC however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 63.49 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 63.49. The average price that TECH shares were previous bought at was USD 58.2868. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in TECH has increased by USD 372,171 compared to the previous valuation of Bio-Techne Corp however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| TECN.SW - | HOLD | 0 @ CHF 169.617 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 169.617. The average price that TECN.SW shares were previous bought at was CHF 202.814. The current market price is -16.4% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 45,622 (USD $56,416) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 32.03 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 32.03. The average price that TGTX shares were previous bought at was USD 34.3438. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in TGTX has increased by USD 13,797 compared to the previous valuation of TG Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 586.07 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 586.07. The average price that TMO shares were previous bought at was USD 407.896. The current market price is 43.7% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 50,522 compared to the previous valuation of Time Out Group plc |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 21.47 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 21.47. The average price that TNDM shares were previous bought at was USD 22.0991. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in TNDM has increased by USD 15,118 compared to the previous valuation of Tandem Diabetes Care Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 29.33 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 29.33. The average price that TWST shares were previous bought at was USD 42.9063. The current market price is -31.6% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 50,769 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 20.13 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 20.13. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 68.1% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 238,845 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 20.13 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 20.13. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 68.1% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 238,845 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 272.211 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 272.211. The average price that UCB.BR shares were previous bought at was EUR 188.363. The current market price is 44.5% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 333,517 (USD $383,798) compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 46.7 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 46.7. The average price that VCYT shares were previous bought at was USD 31.3293. The current market price is 49.1% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 241,201 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.12 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.12. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -23.9% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 54,453 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.12 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.12. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -23.9% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 54,453 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.37891 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.37891. The average price that VLA.PA shares were previous bought at was EUR 2.86092. The current market price is 53.1% higher than average price they were purchased at. The value of the holding in VLA.PA has increased by EUR 7,523 (USD $8,657) compared to the previous valuation of Valneva SE however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.89 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.89. The average price that VNDA shares were previous bought at was USD 4.49047. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in VNDA has increased by USD 6,162 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 32.03 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 32.03. The average price that VRDN shares were previous bought at was USD 19.65. The current market price is 63.0% higher than average price they were purchased at. The value of the holding in VRDN has increased by USD 167,163 compared to the previous valuation of Viridian Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 18.8277 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 18.8277. The average price that XVIVO.ST shares were previous bought at was SEK 42.7002. The current market price is -55.9% lower than average price they were purchased at. The value of the holding in XVIVO.ST has increased by SEK 49,699 (USD $5,210) compared to the previous valuation of however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 24.99 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 24.99. The average price that ZYME shares were previous bought at was USD 14.3. The current market price is 74.8% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 60,353 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | SELL | -6,875 @ KRW 1211.53 | KRW -8,329,269 | The ETF sold 6875 shares of 207940.KS on 2025-11-24. The shares were previously bought for an average price of KRW 720.393. The SAMSUNG BIOLOGICS LTD shares were sold for 68.2% higher than average price of previous purchases. This sale made a profit of KRW 3,376,567 (USD $2,301) The average price that the ETF previously sold 207940.KS share for is KRW 727.196 so the ETF has sold 6875 shares on 2025-11-24 at a higher price than the previous selling average. |